Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA‐REG OUTCOME® trial

by Takashi Kadowaki, Masaomi Nangaku, Stefan Hantel, Tomoo Okamura, Maximilian vonEynatten, Christoph Wanner, Audrey Koitka‐Weber
Published 2019-05-01

Safety and tolerability of empagliflozin in East Asian patients with type 2 diabetes: Pooled analysis of phase I–III clinical trials

by Daisuke Yabe, Atsutaka Yasui, Linong Ji, Moon‐Kyu Lee, Ronald Ching Wan Ma, Tien‐Jyun Chang, Tomoo Okamura, Cordula Zeller, Stefan Kaspers, Jisoo Lee, Sven Kohler, Yutaka Seino
Published 2019-03-01